A Phase 2 interventional study of BIMERVAX in SARS CoV 2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 7 sites in Spain. Open to participants aged 12 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Hipra Scientific, S.L.U · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.
Among the 401 studies in COVID-19 with a site in Spain, this one is the 93rd largest by enrollment of the 254 interventional ones that give a count, is one of 22 that started in 2023, is one of 54 in phase 2, and was the 375th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 21 more countries
Ages 18+
PEACHES BIOTECH · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
401 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 84 · Phase 3 90 · Phase 4 14
First in 2015; this study’s year is marked. 22 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 242 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 132 across the 254 interventional studies, 600 across the 146 observational. Of the 287 that completed or were terminated, 73 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 401 have an industry lead sponsor. The 10 most frequent:
Hipra Scientific, S.L.U is the lead sponsor of 8 studies on the registry; none are open to participants now.
Hipra Scientific, S.L.U has 8 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
8 of the studies in COVID-19 with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06544395Clinica Gema LeonEfficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae | 2026-12-01 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 401 studies in COVID-19 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.
This was a Phase IIb, open-label, single-agent, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.
In this study a total of 300 adolescents from 12 to less than 18 years old were to be enrolled and followed for 12 months.
The immunogenicity was to be evaluated in at least 154 adolescents with no documented medical history of SARS-CoV-2 infection, who had previously received two doses of Comirnaty® vaccine.
The safety assessment was to be evaluated in at least 300 adolescents who had previously received two doses of Comirnaty® vaccine.
All participants received a single heterologous booster dose of BIMERVAX®, at least 6 months after their second dose of Comirnaty® vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has agreed to continue adequate contraception or abstinence through 3 months following the booster dose.
Participants with female reproductive system:
Participants with male reproductive system:
Exclusion Criteria:
Note: This includes both conditions that may increase the risk associated with study intervention administration or a condition that may interfere with the interpretation of study results.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of 40μg of BIMERVAX, administered intramuscularly
Biological: BIMERVAX
One dose of 40μg of BIMERVAX, administered intramuscularly
Changes in immunogenicity against Omicron BA.1
Neutralisation titre against Omicron BA.1 measured as inhibitory concentration 50 (IC50) by PBNA and reported as log10 concentration for each individual sample at Baseline and Day 14.
Time frame: 14 days
Changes in immunogenicity against Omicron BA.1
Geometric Mean Titre (GMT) for group comparison with HIPRA-HH-2 at Baseline and Day 14.
Time frame: 14 days
Incidence of solicited local and systemic reactions (Safety and tolerability of PHH-1V)
Solicited local and systemic reactions through Day 7 after vaccination.
Time frame: 7 days
Incidence of unsolicited local and systemic adverse events (Safety and tolerability of PHH-1V)
Unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination.
Time frame: 28 days
Incidence of related adverse events and serious adverse events (Safety and tolerability of PHH-1V)
Related adverse events (AEs) and all serious adverse events (SAEs) through the end of the study.
Time frame: 1 year
Incidence of adverse events of special interest (Safety and tolerability of PHH-1V)
Adverse event of special interest (AESI) through the end of the study.
Time frame: 1 year
Incidence of related medically attended adverse events (Safety and tolerability of PHH-1V)
Related medically attended adverse events (MAAE) through the end of the study.
Time frame: 1 year
Incidence of Grade 2, Grade 3 and Grade 4 changes in safety laboratory parameters (Safety and tolerability of PHH-1V)
Grade 2, Grade 3 and Grade 4 changes from Baseline in safety laboratory parameters through Day 14 after vaccination.
Time frame: 14 days
Changes in immunogenicity against VOCs
Neutralisation titre against VOCs (at least Beta and Delta) measured as IC50 by PBNA and reported as log10 concentration for each individual sample at Baseline and Days 14, 84, 168 and 336.
Time frame: Days 14, 84, 168 and 336
Changes in immunogenicity against VOCs
GMT at Baseline and Days 14, 84, 168 and 336.
Time frame: Days 14, 84, 168 and 336
Changes in immunogenicity against Omicron BA.1 and VOCs
GMFR in neutralising antibodies titres against Omicron BA.1 and VOCs (at least Beta and Delta) at Baseline and Day 14.
Time frame: Day 14
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2023 to primary completion in Sep 2025, 27 months.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 27 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hipra Scientific, S.L.U